Search

Your search keyword '"Newsom-Davis T"' showing total 221 results
Start Over Author "Newsom-Davis T"
221 results on '"Newsom-Davis T"'

2. 60 CONTACT-01: Efficacy and safety from a phase III study of atezolizumab (atezo) + cabozantinib (cabo) vs docetaxel (doc) monotherapy in patients (pts) with metastatic NSCLC (mNSCLC) previously treated with checkpoint inhibitors and chemotherapy

Author

Neal, J., primary, Pavlakis, N., additional, Kim, S-W., additional, Goto, Y., additional, Lim, S.M., additional, Mountzios, G., additional, Fountzilas, E., additional, Mochalova, A., additional, Christoph, D.C.C., additional, Bearz, A., additional, Quantin, X., additional, Palmero, R., additional, Antic, V., additional, Chun, E., additional, Edubilli, T. Rao, additional, Lin, Y-C., additional, Huseni, M., additional, Scheffold, C., additional, Vervaet, P., additional, and Newsom-Davis, T., additional

Published
2023
Full Text
View/download PDF

3. A multicentre study of pembrolizumab time-of-day infusion patterns and clinical outcomes in non-small-cell lung cancer: too soon to promote morning infusions

Author

Cortellini, A., primary, Barrichello, A.P.C., additional, Alessi, J.V., additional, Ricciuti, B., additional, Vaz, V.R., additional, Newsom-Davis, T., additional, Evans, J.S., additional, Lamberti, G., additional, Pecci, F., additional, Viola, P., additional, D’Alessio, A., additional, Fulgenzi, C.A.M., additional, Awad, M.M., additional, and Pinato, D.J., additional

Published
2022
Full Text
View/download PDF

4. 1116P United Kingdom real-world experience of sotorasib in KRAS G12C mutant non-small cell lung cancer: A British thoracic oncology group review

Author

Julve, M., primary, Kennedy, O., additional, Lindsay, C., additional, Walters-Davies, R., additional, Button, M.R., additional, Steele, N., additional, McGeogh, A., additional, Georgiou, A., additional, Goranov, B., additional, Farrugia, D., additional, Gorf, L., additional, Remer, M., additional, Shah, R., additional, Baijal, S., additional, Gennatas, S., additional, Geldart, T., additional, Daniels, E., additional, Watts, L., additional, Greystoke, A., additional, and Newsom-Davis, T., additional

Published
2022
Full Text
View/download PDF

6. OA02.03 Amivantamab Plus Lazertinib vs Osimertinib in First-line EGFR-mutant Advanced NSCLC: Longer Follow-up of the MARIPOSA Study

Author

Gadgeel, S., Cho, B.C., Lu, S., Felip, E., Hayashi, H., Spira, A.I., Besse, B., Thomas, M., Owen, S., Kim, Y.J., Lee, S.-H., Mourão Dias, J., Lee, Y.-G., Zhao, Y., Fang, Y., Girard, N., Liu, Z., Sun, P., Oliveira, S.C. Sousa, Shen, H., Paz-Ares, L., Matsumoto, S., Tanaka, H., Ahmad, A.R., Andabekov, T., Sunpaweravong, P., Ozyilkan, O., Yang, J.C.-H., Gottfried, M., Hernandez, O., Kimmich, M., Cortinovis, D., Kaen, D.L., Montes, L.V. García, Popat, S., Newsom-Davis, T., Xie, J., Sun, T., Fennema, E., Daksh, M., Ennis, M., Sethi, S., Bauml, J.M., and Nguyen, D.

Published
2024
Full Text
View/download PDF

8. Presenting features and early mortality from SARS-CoV-2 infection in cancer patients during the initial stage of the COVID-19 pandemic in Europe

Author

Pinato, D, Lee, A, Biello, F, Segui, E, Aguilar-Company, J, Carbo, A, Bruna, R, Bower, M, Rizzo, G, Benafif, S, Carmona, C, Chopra, N, Cruz, C, D'Avanzo, F, Evans, J, Galazi, M, Garcia-Fructuoso, I, Pria, A, Newsom-Davis, T, Ottaviani, D, Patriarca, A, Reyes, R, Sharkey, R, Sng, C, Wong, Y, Ferrante, D, Scotti, L, Avanzi, G, Bellan, M, Castello, L, Marco-Hernandez, J, Molla, M, Pirisi, M, Ruiz-Camps, I, Sainaghi, P, Gaidano, G, Brunet, J, Tabernero, J, Prat, A, Gennari, A, Pinato D. J., Lee A. J. X., Biello F., Segui E., Aguilar-Company J., Carbo A., Bruna R., Bower M., Rizzo G., Benafif S., Carmona C., Chopra N., Cruz C. A., D'avanzo F., Evans J. S., Galazi M., Garcia-Fructuoso I., Pria A. D., Newsom-Davis T., Ottaviani D., Patriarca A., Reyes R., Sharkey R., Sng C. C. T., Wong Y. N. S., Ferrante D., Scotti L., Avanzi G. C., Bellan M., Castello L. M., Marco-Hernandez J., Molla M., Pirisi M., Ruiz-Camps I., Sainaghi P. P., Gaidano G., Brunet J., Tabernero J., Prat A., Gennari A., Pinato, D, Lee, A, Biello, F, Segui, E, Aguilar-Company, J, Carbo, A, Bruna, R, Bower, M, Rizzo, G, Benafif, S, Carmona, C, Chopra, N, Cruz, C, D'Avanzo, F, Evans, J, Galazi, M, Garcia-Fructuoso, I, Pria, A, Newsom-Davis, T, Ottaviani, D, Patriarca, A, Reyes, R, Sharkey, R, Sng, C, Wong, Y, Ferrante, D, Scotti, L, Avanzi, G, Bellan, M, Castello, L, Marco-Hernandez, J, Molla, M, Pirisi, M, Ruiz-Camps, I, Sainaghi, P, Gaidano, G, Brunet, J, Tabernero, J, Prat, A, Gennari, A, Pinato D. J., Lee A. J. X., Biello F., Segui E., Aguilar-Company J., Carbo A., Bruna R., Bower M., Rizzo G., Benafif S., Carmona C., Chopra N., Cruz C. A., D'avanzo F., Evans J. S., Galazi M., Garcia-Fructuoso I., Pria A. D., Newsom-Davis T., Ottaviani D., Patriarca A., Reyes R., Sharkey R., Sng C. C. T., Wong Y. N. S., Ferrante D., Scotti L., Avanzi G. C., Bellan M., Castello L. M., Marco-Hernandez J., Molla M., Pirisi M., Ruiz-Camps I., Sainaghi P. P., Gaidano G., Brunet J., Tabernero J., Prat A., and Gennari A.

Abstract

We describe the outcomes in cancer patients during the initial outbreak of the COVID-19 in Europe from the retrospective, multi-center observational OnCovid study. We identified 204 cancer patients from eight centers in the United Kingdom, Italy, and Spain aged > 18 (mean = 69) and diagnosed with COVID-19 between February 26th and April 1st, 2020. A total of 127 (62%) were male, 184 (91%) had a diagnosis of solid malignancy, and 103 (51%) had non-metastatic disease. A total of 161 (79%) had > 1 co-morbidity. A total of 141 (69%) patients had > 1 COVID-19 complication. A total of 36 (19%) were escalated to high-dependency or intensive care. A total of 59 (29%) died, 53 (26%) were discharged, and 92 (45%) were in-hospital survivors. Mortality was higher in patients aged > 65 (36% versus 16%), in those with > 2 co-morbidities (40% versus 18%) and developing > 1 complication from COVID-19 (38% versus 4%, p = 0.004). Multi-variable analyses confirmed age > 65 and > 2 co-morbidities to predict for patient mortality independent of tumor stage, active malignancy, or anticancer therapy. During the early outbreak of SARS-CoV-2 infection in Europe co-morbid burden and advancing age predicted for adverse disease course in cancer patients. The ongoing OnCovid study will allow us to compare risks and outcomes in cancer patients between the initial and later stages of the COVID-19 pandemic.

Published
2020

10. 9P Final results from TAIL: Updated long-term safety and efficacy of atezolizumab (atezo) in a diverse population of patients (pts) with previously treated advanced NSCLC

Author

Ardizzoni, A., primary, Azevedo, S., additional, Rubio-Viqueira, B., additional, Rodriguez-Abreu, D., additional, Alatorre-Alexander, J., additional, Smit, H.J.M., additional, Yu, J., additional, Syrigos, K., additional, Hoglander, E., additional, Kaul, M., additional, Tolson, J., additional, Hu, Y., additional, Vollan, H.K., additional, and Newsom-Davis, T., additional

Published
2022
Full Text
View/download PDF

11. Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study

Author

Pinato, DJ, Aguilar-Company, J, Ferrante, D, Hanbury, G, Bower, M, Salazar, R, Mirallas, O, Sureda, A, Plaja, A, Cucurull, M, Mesia, R, Townsend, S, Jackson, A, Dalla Pria, A, Newsom-Davis, T, Handford, J, Sita-Lumsden, A, Apthorp, E, Vincenzi, B, Bertuzzi, A, Brunet, J, Lambertini, M, Maluquer, C, Pedrazzoli, P, Biello, F, Sinclair, A, Bawany, S, Khalique, S, Rossi, S, Rogers, L, Murphy, C, Belessiotis, K, Carmona-Garcia, MC, Sharkey, R, Garcia-Illescas, D, Rizzo, G, Perachino, M, Saoudi-Gonzalez, N, Doonga, K, Fox, L, Roldan, E, Gaidano, G, Ruiz-Camps, I, Bruna, R, Patriarca, A, Martinez-Vila, C, Cantini, L, Zambelli, A, Giusti, R, Mazzoni, F, Caliman, E, Santoro, A, Grosso, F, Parisi, A, Queirolo, P, Aujayeb, A, Rimassa, L, Prat, A, Tucci, M, Libertini, M, Grisanti, S, Mukherjee, U, Diamantis, N, Fusco, V, Generali, D, Provenzano, S, Gennari, A, Tabernero, J, and Cortellini, A

Abstract

Background The omicron (B.1.1.529) variant of SARS-CoV-2 is highly transmissible and escapes vaccine-induced immunity. We aimed to describe outcomes due to COVID-19 during the omicron outbreak compared with the prevaccination period and alpha (B.1.1.7) and delta (B.1.617.2) waves in patients with cancer in Europe. Methods In this retrospective analysis of the multicentre OnCovid Registry study, we recruited patients aged 18 years or older with laboratory-confirmed diagnosis of SARS-CoV-2, who had a history of solid or haematological malignancy that was either active or in remission. Patient were recruited from 37 oncology centres from UK, Italy, Spain, France, Belgium, and Germany. Participants were followed up from COVID-19 diagnosis until death or loss to follow-up, while being treated as per standard of care. For this analysis, we excluded data from centres that did not actively enter new data after March 1, 2021 (in France, Germany, and Belgium). We compared measures of COVID-19 morbidity, which were complications from COVID-19, hospitalisation due to COVID-19, and requirement of supplemental oxygen and COVID-19-specific therapies, and COVID-19 mortality across three time periods designated as the prevaccination (Feb 27 to Nov 30, 2020), alpha-delta (Dec 1, 2020, to Dec 14, 2021), and omicron (Dec 15, 2021, to Jan 31, 2022) phases. We assessed all-cause case-fatality rates at 14 days and 28 days after diagnosis of COVID-19 overall and in unvaccinated and fully vaccinated patients and in those who received a booster dose, after adjusting for country of origin, sex, age, comorbidities, tumour type, stage, and status, and receipt of systemic anti-cancer therapy. This study is registered with ClinicalTrials.gov, NCT04393974, and is ongoing. Findings As of Feb 4, 2022 (database lock), the registry included 3820 patients who had been diagnosed with COVID-19 between Feb 27, 2020, and Jan 31, 2022. 3473 patients were eligible for inclusion (1640 [47.4%] were women and 1822 [52.6%] were men, with a median age of 68 years [IQR 57-77]). 2033 (58.5%) of 3473 were diagnosed during the prevaccination phase, 1075 (31.0%) during the alpha-delta phase, and 365 (10.5%) during the omicron phase. Among patients diagnosed during the omicron phase, 113 (33.3%) of 339 were fully vaccinated and 165 (48.7%) were boosted, whereas among those diagnosed during the alpha-delta phase, 152 (16.6%) of 915 were fully vaccinated and 21 (2.3%) were boosted. Compared with patients diagnosed during the prevaccination period, those who were diagnosed during the omicron phase had lower case-fatality rates at 14 days (adjusted odds ratio [OR] 0.32 [95% CI 0.19-0.61) and 28 days (0.34 [0.16-0.79]), complications due to COVID-19 (0.26 [0.17-0.46]), and hospitalisation due to COVID-19 (0.17 [0.09-0.32]), and had less requirements for COVID-19-specific therapy (0.22 [0.15-0.34]) and oxygen therapy (0.24 [0.14-0.43]) than did those diagnosed during the alpha-delta phase. Unvaccinated patients diagnosed during the omicron phase had similar crude case-fatality rates at 14 days (ten [25%] of 40 patients vs 114 [17%] of 656) and at 28 days (11 [27%] of 40 vs 184 [28%] of 656) and similar rates of hospitalisation due to COVID-19 (18 [43%] of 42 vs 266 [41%] of 652) and complications from COVID-19 (13 [31%] of 42 vs 237 [36%] of 659) as those diagnosed during the alpha-delta phase. Interpretation Despite time-dependent improvements in outcomes reported in the omicron phase compared with the earlier phases of the pandemic, patients with cancer remain highly susceptible to SARS-CoV-2 if they are not vaccinated against SARS-CoV-2. Our findings support universal vaccination of patients with cancer as a protective measure against morbidity and mortality from COVID-19. Copyright (C) 2022. Published by Elsevier Ltd. All rights reserved.

Published
2022

12. 1565MO Time-dependent improvement in the clinical outcomes from COVID-19 in cancer patients: An updated analysis of the OnCovid registry

Author

Pinato, D.J., primary, Patel, M., additional, Lambertini, M., additional, Colomba, E., additional, Pommeret, F., additional, Van Hemelrijick, M., additional, Zambelli, A., additional, Newsom-Davis, T., additional, Salazar, R., additional, Bertuzzi, A., additional, Gaidano, G., additional, Rizzo, G., additional, Patel, G., additional, Felip, E., additional, Prat, A., additional, Aguilar-Company, J., additional, Tabernero, J., additional, Diamantis, N., additional, Gennari, A., additional, and Cortellini, A., additional

Published
2021
Full Text
View/download PDF

13. Primary results from TAIL: A global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer

Author

Ardizzoni, A. Azevedo, S. Rubio-Viqueira, B. Rodríguez-Abreu, D. Alatorre-Alexander, J. Smit, H.J.M. Yu, J. Syrigos, K. Trunzer, K. Patel, H. Tolson, J. Cardona, A. Perez-Moreno, P.D. Newsom-Davis, T.

Abstract

Background Atezolizumab treatment improves survival, with manageable safety, in patients with previously treated advanced/metastatic non-small cell lung cancer. The global phase III/IV study TAIL (NCT03285763) was conducted to evaluate the safety and efficacy of atezolizumab monotherapy in a clinically diverse population of patients with previously treated non-small cell lung cancer, including those not eligible for pivotal trials. Methods Patients with stage IIIB/IV non-small cell lung cancer whose disease progressed after 1-2 lines of chemotherapy were eligible for this open-label, single-arm, multicenter study, including those with severe renal impairment, an Eastern Cooperative Oncology Group performance status of 2, prior anti-programmed death 1 (PD-1) therapy, and autoimmune disease. Atezolizumab was administered intravenously (1200 mg every 3 weeks). Coprimary endpoints were treatment-related serious adverse events and immune-related adverse events. Results 619 patients enrolled and 615 received atezolizumab. At data cutoff, the median follow-up was 12.6 months (95% CI 11.9 to 13.1). Treatment-related serious adverse events occurred in 7.8% and immune-related adverse events in 8.3% of all patients and as follows, respectively, in these subgroups: renal impairment (n=78), 11.5% and 12.8%; Eastern Cooperative Oncology Group performance status of 2 (n=61), 14.8% and 8.2%; prior anti-PD-1 therapy (n=39), 5.1% and 7.7%; and autoimmune disease (n=30), 6.7% and 10.0%. No new safety signals were reported. In the overall population, the median overall survival was 11.1 months (95% CI 8.9 to 12.9), the median progression-free survival was 2.7 months (95% CI 2.1 to 2.8) and the objective response rate was 11%. Conclusions This study confirmed the benefit-risk profile of atezolizumab monotherapy in a clinically diverse population of patients with previously treated non-small cell lung cancer. These safety and efficacy outcomes may inform treatment decisions for patients generally excluded from checkpoint inhibitor trials. © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Published
2021

14. Clinical portrait of the SARS-Cov-2 epidemic in European cancer patients

Author

Pinato DJ, Zambelli A, Aguilar-Company J, Bower M, Sng C, Salazar R, Bertuzzi A, Brunet J, Mesia R, Segui E, Biello F, Generali D, Grisanti S, Rizzo G, Libertini M, Maconi A, Harbeck N, Vincenzi B, Bertulli R, Ottaviani D, Carbo A, Bruna R, Benafif S, Marrari A, Wuerstlein R, Carmona-Garcia MC, Chopra N, Tondini C, Mirallas O, Tovazzi V, Betti M, Provenzano S, Fotia V, Cruz CA, Dalla Pria A, D'Avanzo F, Evans JS, Saoudi-Gonzalez N, Felip E, Galazi M, Garcia-Fructuoso I, Lee AJX, Newsom-Davis T, Patriarca A, Garcia-Illescas D, Reyes R, Dileo P, Sharkey R, Wong YNS, Ferrante D, Marco-Hernandez J, Sureda A, Maluquer C, Ruiz-Camps I, Gaidano G, Rimassa L, Chiudinelli L, Izuzquiza M, Cabirta A, Franchi M, Santoro A, Prat A, Tabernero J, Gennari A, Wellcome Trust, and Cancer Treatment & Research Trust

Subjects
1112 Oncology and Carcinogenesis
Abstract

The SARS-Cov-2 pandemic significantly impacted on oncology practice across the globe. There is uncertainty as to the contribution of patients' demographics and oncological features on severity and mortality from Covid-19 and little guidance as to the role of anti-cancer and anti-Covid-19 therapy in this population. In a multi-center study of 890 cancer patients with confirmed Covid-19 we demonstrated a worsening gradient of mortality from breast cancer to haematological malignancies and showed that male gender, older age, and number of co-morbidities identifies a subset of patients with significantly worse mortality rates from Covid-19. Provision of chemotherapy, targeted therapy and immunotherapy did not worsen mortality. Exposure to antimalarials was associated with improved mortality rates independent of baseline prognostic factors. This study highlights the clinical utility of demographic factors for individualized risk-stratification of patients and support further research into emerging anti-Covid-19 therapeutics in SARS-Cov-2 infected cancer patients.

Published
2020

15. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study

Author

Lee, LY, Cazier, J-B, Angelis, V, Arnold, R, Bisht, V, Campton, NA, Chackathayil, J, Cheng, VW, Curley, HM, Fittall, MW, Freeman-Mills, L, Gennatas, S, Goel, A, Hartley, S, Hughes, DJ, Kerr, D, Lee, AJ, Lee, RJ, McGrath, SE, Middleton, CP, Murugaesu, N, Newsom-Davis, T, Okines, AF, Olsson-Brown, AC, Palles, C, Pan, Y, Pettengell, R, Powles, T, Protheroe, EA, Purshouse, K, Sharma-Oates, A, Sivakumar, S, Smith, AJ, Starkey, T, Turnbull, CD, Várnai, C, Yousaf, N, Team, UK Coronavirus Monitoring Project, Kerr, R, and Middleton, G

Subjects
Male, medicine.medical_specialty, Coronavirus Infections/complications, Comorbidity, Disease, 030204 cardiovascular system & hematology, Betacoronavirus, 03 medical and health sciences, Sex Factors, 0302 clinical medicine, Risk Factors, Cause of Death, Internal medicine, Clinical endpoint, Humans, Medicine, Neoplasms/complications, Prospective Studies, 030212 general & internal medicine, Prospective cohort study, Pandemics, Aged, Cause of death, Manchester Cancer Research Centre, business.industry, ResearchInstitutes_Networks_Beacons/mcrc, Age Factors, Antineoplastic Agents/therapeutic use, Cancer, Odds ratio, General Medicine, Middle Aged, medicine.disease, Female, Observational study, Pneumonia, Viral/complications, business
Abstract

Background Individuals with cancer, particularly those who are receiving systemic anticancer treatments, have been postulated to be at increased risk of mortality from COVID-19. This conjecture has considerable effect on the treatment of patients with cancer and data from large, multicentre studies to support this assumption are scarce because of the contingencies of the pandemic. We aimed to describe the clinical and demographic characteristics and COVID-19 outcomes in patients with cancer. Methods In this prospective observational study, all patients with active cancer and presenting to our network of cancer centres were eligible for enrolment into the UK Coronavirus Cancer Monitoring Project (UKCCMP). The UKCCMP is the first COVID-19 clinical registry that enables near real-time reports to frontline doctors about the effects of COVID-19 on patients with cancer. Eligible patients tested positive for severe acute respiratory syndrome coronavirus 2 on RT-PCR assay from a nose or throat swab. We excluded patients with a radiological or clinical diagnosis of COVID-19, without a positive RT-PCR test. The primary endpoint was all-cause mortality, or discharge from hospital, as assessed by the reporting sites during the patient hospital admission. Findings From March 18, to April 26, 2020, we analysed 800 patients with a diagnosis of cancer and symptomatic COVID-19. 412 (52%) patients had a mild COVID-19 disease course. 226 (28%) patients died and risk of death was significantly associated with advancing patient age (odds ratio 9·42 [95% CI 6·56–10·02]; p Interpretation Mortality from COVID-19 in cancer patients appears to be principally driven by age, gender, and comorbidities. We are not able to identify evidence that cancer patients on cytotoxic chemotherapy or other anticancer treatment are at an increased risk of mortality from COVID-19 disease compared with those not on active treatment. Funding University of Birmingham, University of Oxford.

Published
2020
Full Text
View/download PDF

17. 1679P Determinants of mortality from SARS-CoV-2 infection in European cancer patients

Author

Pinato, D.J., primary, Sng, C., additional, Wong, Y.N.S., additional, Biello, F., additional, Seguí, E., additional, Aguilar-Company, J., additional, Carbo Bague, A., additional, Patriarca, A., additional, Bower, M.D., additional, Rizzo, G., additional, Bruna, R., additional, Cruz, C.A., additional, D'Avanzo, F., additional, Newsom-Davis, T., additional, Mollà, M., additional, Gaidano, G., additional, Brunet, J., additional, Tabernero, J., additional, Prat, A., additional, and Gennari, A., additional

Published
2020
Full Text
View/download PDF

28. Primary results from TAIL, a global single-arm safety study of atezolizumab (atezo) monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer (NSCLC)

Author

Ardizzoni, A., primary, Azevedo, S., additional, Rubio Viquiera, B., additional, Rodriguez Abreu, D., additional, Alatorre-Alexander, J., additional, Smit, H.J., additional, Yu, J., additional, Syrigos, K., additional, Patel, H., additional, Tolson, J., additional, Cardona, A., additional, Perez Moreno, P., additional, and Newsom-Davis, T., additional

Published
2019
Full Text
View/download PDF

30. Brigatinib experience on the ALK project

Author

Gomes, F., primary, Tokaca, N., additional, Yip, K., additional, Ghosh, S., additional, Newsom-Davis, T., additional, Greystoke, A., additional, Mills, H., additional, Ahmed, S., additional, Harle, A.S., additional, Ayre, G., additional, Shah, R., additional, Popat, S., additional, Blackhall, F.H., additional, and Summers, Y., additional

Published
2019
Full Text
View/download PDF

34. The ALK project: a real-world national network and database

Author

Gomes, F., primary, Yip, K., additional, Tokaca, N., additional, Greystoke, A., additional, Escriu, C., additional, Conibear, J., additional, Ghosh, S., additional, Doherty, G.J., additional, Funingana, I., additional, Ahmad, T., additional, Ahmed, S., additional, Cox, R.A., additional, Newsom-Davis, T., additional, Mills, H., additional, Shah, R., additional, Dorey, N., additional, Harle, A., additional, Dancey, G., additional, Baijal, S., additional, Geldart, T., additional, Ghafoor, Q., additional, Tarver, K., additional, Talbot, T., additional, Forster, M., additional, Cove-Smith, L., additional, Califano, R., additional, Blackhall, F., additional, Popat, S., additional, and Summers, Y., additional

Published
2019
Full Text
View/download PDF

36. Real-world outcomes with pembrolizumab in patients with treatment-naive advanced/metastatic NSCLC in the UK: multicentre retrospective observational study

Author

Tokaca, N., primary, Gomes, F., additional, Lau, S., additional, Jackson, A., additional, Gradwell, M., additional, Gyi, M., additional, Reinius, M., additional, Valentine, E., additional, Winn, E., additional, Bhosle, J., additional, O’Brien, M., additional, Yousaf, N., additional, Blackhall, F., additional, Gilligan, D., additional, Treece, S., additional, Yip, K., additional, Geldart, T., additional, Baluch, S., additional, Gulliford, T., additional, Muthuramalingam, S., additional, Dancey, G., additional, Britten, A., additional, Brock, J., additional, Stokoe, J., additional, Jain, P., additional, Franks, K., additional, Toy, E., additional, Newsom-Davis, T., additional, Khan, O., additional, Greystoke, A., additional, Ali, C., additional, Leonard, P., additional, Summers, Y., additional, and Popat, S., additional

Published
2019
Full Text
View/download PDF

38. The prognostic and predictive role of hyponatremia in patients with advanced non-small cell lung cancer (NSCLC) with bone metastases

Author

Rinaldi, S., primary, Santoni, M., additional, Leoni, G., additional, Fiordoliva, I., additional, Marcantognini, G., additional, Meletani, T., additional, Armento, G., additional, Santini, D., additional, Newsom-Davis, T., additional, Tiberi, M., additional, Morgese, F., additional, Torniai, M., additional, Bower, M., additional, and Berardi, Rossana, additional

Published
2018
Full Text
View/download PDF

39. P2.13-01 Brigatinib Use in England – Where Next?

Author

Gomes, F., primary, Yip, K., additional, Blackhall, F., additional, Greystoke, A., additional, Califano, R., additional, Ghosh, S., additional, Newsom-Davis, T., additional, Mills, H., additional, Ahmed, S., additional, Harle, A., additional, and Summers, Y., additional

Published
2018
Full Text
View/download PDF

43. Non-small cell lung cancers (NSCLC) and programmed death ligand 1 (PD-L1) testing: multicentric analysis of clinical, pathological and molecular features

Author

Elshiekh, M., primary, Mani, A., additional, Kitson, R., additional, Josephides, E., additional, Clifford, A., additional, Desai, S., additional, Gupta, N., additional, Bowen, F., additional, Berry, M., additional, Bloch, S., additional, Ross, C., additional, Counihan, I., additional, Anderson, J.R., additional, Nandi, J., additional, Roddie, M., additional, Copley, S., additional, Hatcher, O., additional, Denton, A., additional, Power, D., additional, Lewanski, C., additional, Newsom-Davis, T., additional, and Viola, P., additional

Published
2018
Full Text
View/download PDF

45. Retrospective analysis of outcomes in UK patients with advanced NSCLC and ROS1 rearrangement

Author

Tokaca, N., primary, Pouptsis, A., additional, Karapanagiotou, E., additional, Spicer, J., additional, Halkyard, E., additional, Blackhall, F., additional, Summers, Y., additional, Greystoke, A., additional, Bhosle, J., additional, Jones, A., additional, Newsom-Davis, T., additional, Nicolson, M., additional, O’Brien, M., additional, Yousaf, N., additional, and Popat, S., additional

Published
2018
Full Text
View/download PDF

47. Circulating tumour DNA (ctDNA) in the clinical management of patients (pts) with advanced non-small cell lung cancer (NSCLC): A single centre experience

Author

Uccello, M., primary, Kushnir, M., additional, Mak, G., additional, Murias Henriquez, C., additional, Abbosh, C., additional, Papadatos-Pastos, D., additional, Newsom-Davis, T., additional, Ahmad, T., additional, Swanton, C., additional, Forster, M., additional, Lanman, R., additional, Faull, I., additional, and Arkenau, H-T., additional

Published
2017
Full Text
View/download PDF

50. 69: Outcomes with nintedanib and docetaxel in patients with relapsed NSCLC adenocarcinoma treated within the UK Nintedanib Individual Patient Supply programme

Author

Tokaca, N., primary, Crawford, M.S., additional, Greystoke, A., additional, Appel, W., additional, Lal, R., additional, Steele, N., additional, Ali, C., additional, Bezecny, P., additional, Fernando, S., additional, Karapanagiotou, E., additional, Skailes, G., additional, Dorey, N., additional, Harrow, S., additional, Bhosle, J., additional, Khan, O., additional, Newsom-Davis, T., additional, Spicer, J., additional, Toy, L., additional, O'Brien, M., additional, Gunapala, R., additional, Lu, S.K., additional, and Popat, S., additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results